2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

801. Gene Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Emerging Technologies, Gene Editing, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Transplantation, Vaccines, Gene Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Genomics, Diseases, Bleeding and Clotting, Hemophilia, Bone Marrow Failure Syndromes, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4303 mRNA-expressing functionalized virus-like particles provide a modular strategy for in vivo anti-tumor activity against both hematologic malignancies and solid tumors

Frances Maureen Rocamora, PhD, Matthew S Kim, PhD2, Barbara S Perez3, Vivian Le4, James Cusack5, Edith Lopez6, Luisjesus S Cruz, PhD7, Enaaya Mahmood8, Sneha Doddapaneni9, Trinidad Kellemen10, Dan S Kaufman, MD, PhD11
1 University of California San Diego, La Jolla, California, United States
2 University of California San Diego, La Jolla, California, United States
3 University of California San Francisco, San Francisco, California, United States
4 University of California San Diego, La Jolla, United States
5 University of California San Diego, La Jolla, California, United States
6 University of California San Diego, La Jolla, California, United States
7 University of California San Diego, La Jolla, California, United States
8 University of California San Diego, La Jolla, California, United States
9 University of California San Diego, La Jolla, California, United States
10 University of California San Diego, La Jolla, California, United States
11 University of California San Diego, La Jolla, California, United States

In vivo immune cell engineering aims to overcome the limits of ex vivo manufactured cells by generating therapeutic cells directly within patients. Current efforts in the field demonstrate success using lentivirus-based viral vectors (LV) and lipid nanoparticles (LNPs). To address the limitations of conventional chimeric antigen receptor (CAR) T cell manufacturing, we developed a novel in vivo CAR engineering platform based on functionalized virus-like particles that self-assemble with a minimal viral genome to efficiently package and deliver mRNA payloads (mRNA VLPs). This platform combines the ease-of-manufacturing and modularity of viral vectors, while mitigating the risk of insertional mutagenesis associated with genomic integration by conventional LV. 

Comparing the efficiency of transgene delivery in primary human T cells treated with either LV or mRNA-expressing VLPs, we found that while mRNA VLPs lead to transient expression of a GFP reporter, they demonstrated a 1.8-fold higher transduction efficiency (25% vs. 13%, p = 0.002) after 24 hours and a 2.2-fold higher viral genome packaging efficiency (5.63x 109 VG/mL vs 2.6 x 109 VG/mL, p = 0.03) at an equivalent titer as LV.

To further improve this modular gene delivery platform, the mRNA VLP envelope was functionalized in two ways. Specifically, we combine expression of an anti-CD3 scFv with an enhancer molecule that improves T cell viability and proliferation, as well as augments the cytotoxic activity of engineered T cells. Using in vitro co-culture cytotoxicity assays, we found that rested primary human T cells transduced with the dual functionalized mRNA VLPs—bearing both the enhancer and an anti-CD3 scFv—showed significantly superior killing activity compared to only VLPs coated with either anti-CD3 or the enhancer alone. After 48 hours, primary T cells transduced with a dual functionalized anti-CD19 CAR VLP showed ~80% killing of Nalm6 B cells. To test the in vivo efficacy of our anti-CD19 CAR mRNA VLPs, NSG mice were humanized with 10 x 106 PBMCs, and then intravenously injected with 2 x 106 transducing units (TU) of anti-CD19 CAR mRNA VLPs coated with either the enhancer, the anti-CD3 scFv, or both. Spleens and peripheral blood were then harvested 24 hours later. We detected CAR+ T cells in both blood and spleen and observed an overall decrease in the B cell population in all VLP-treated groups compared to the PBS-treated mice, with the greatest depletion in mice treated with VLPs that express both the anti-CD3 scFV and the enhancer molecule.

We then sought to validate the efficacy of our dual-functionalized mRNA VLPs to generate CAR-T cells against solid tumors by packaging an anti-GD2 CAR to target neuroblatoma, as well as an anti-mesothelin (MSLN) CAR to target ovarian cancer cells. In both cases, we found that our dual functionalized mRNA VLPs led to significantly higher transduction rates of resting primary T cells when compared against VSVg-pseudotyped VLPs: 7-fold higher for anti-GD2 CAR (40% vs 5.8% CAR+ T cells, p = 0.002), and 4-fold higher for anti-MSLN CAR (80% vs 19.2% CAR+ T cells, p = 2 x10-6). From in vitro co-culture assays, we likewise found that VLPs expressing both anti-CD3 and the enhancer molecule elicited the most tumor cell clearance. Primary T cells treated with a dual-functionalized anti-GD2 CAR demonstrated almost complete elimination (95%) of GD2-expressiong SH-SY5Y neuroblastoma cells. The dual-functionalized anti-MSLN showed over 50% killing of MSLN-positive A1847 ovarian cancer cells.

In summary, we have developed a novel viral-based, targeted mRNA delivery platform that demonstrates superior transduction and viral packaging efficiencies compared with conventional LV. Furthermore, we have shown that functionalizing the VLP envelope with T cell-targeting and T cell-activating molecules are able to impart significantly improved CAR-T cell activity against both hematologic malignancies and solid tumors. We believe that these mRNA-expressing VLPs provide a promising modular in vivo engineering platform that leverages the tractability of enveloped viruses, and offer a more practical, scalable, and safer system of delivering a diverse repertoire of genetic payloads to many different cell types. Ongoing work includes studies using humanized mouse models to validate in vivo engineering and anti-tumor efficacy, as well as expanding the utility of this platform to other immune effector cells.  

Dan S Kaufman, MD, PhD: No relevant conflicts of interest to declare.